Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

active_not_recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
active_not_recruitingphase_3

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226
active_not_recruitingphase_3

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

NCT03049189

Clinical Trials (2)

Showing 2 of 2 trials
NCT04919226Phase 3

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Active Not Recruiting
NCT03049189Phase 3

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Active Not Recruiting

All 2 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
2